Call Us: +91-779-979-0002/+91-779-979-0003

Plenary Talks

Abstract

Malignant mesenchymal tumours of breast are rare, histologically heterogeneous nonepithelial malignancies that arise from the totipotent mesenchymal cells of the breast stroma. They can develop de novo (primary), after radiation therapy (RT), or in the setting of chronic lymphedema of the arm or breast (therapy related, secondary). The incidence is less than 1% of all primary breast malignancies and less than 5%of all sarcomas. It is reported in fourth and fifth decades of life.The sub-types of breast sarcomas are: malignant fibrous histiocytoma, fibrosarcoma, angiosarcoma ,leiomyosarcoma, liposarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, synovial sarcoma and neurofibrosarcoma as case reports. Extensive sampling and IHC are mndatory to exclude metaplastic carcinoma, carcinosarcoma and malignant phyllodes tumour. FNABC, cell block with HP and IHC help in diagnosis in almost all cases. Recently tru-cut/core biopsy is usually performed for diagnosis. The prognosis depends on tumour type and size, histologic grade and stage. Breast sarcomas also tend to be larger at diagnosis than other types of breast tumors. Although the clinical features of breast sarcoma mimic those of breast carcinoma in some ways, therapy and prognosis differ dramatically. Given the rarity of breast sarcomas, there are no prospective randomized trials to guide therapy. Treatment principles have been derived from small retrospective case reviews of breast sarcomas and extrapolated from studies of non-breast soft tissue sarcomas of the extremity and chest wall since clinical behavior, histology, and prognosis are similar. Surgery represents the only potentially curative modality for breast sarcomas. The type and extent of the operation is based upon both the size of the tumor as well as histology. Negative surgical margins are more important than extent of surgical resection . Clear margin of at least of 1cm from tumour and tumour < 5cms in diameter are favourable factors. Even in the case of large breast sarcomas, the lymph nodes are usually negative for cancer, and axillary node dissection is usually not required. Post-operative radiotherapy is usually administered to prevent recurrence. Role of chemotherapy is doubtful. Prognosis is poor. Five year survival is less than 50% in spite of all modalities of treatment. The gloomy outcome is due to large size of tumour, high grade and extensive local and distant metastasis.

Biography

Dr.Asitava Mondal graduated MBBS from Medical College and Hospital, Kolkata and MD (Pathology) from PGIMER, Chandigarh. He was awarded National Scholarship, 5 years college scholarship. Shank’s Silver Medal, Green Armytage Silver Medal and F.C. Chatterjee Scholarship in Pathology during undergraduate study. He was former teaching Faculty in Institute of Child Health and in DNB in Imaging and Radiodiagnosis , Consultant Cytologist and Oncopathologist Thakurpukur Cancer Centre and SVS Marwari Hospital and Cancer Centre, Kolkata. National President -(IAC) - 2006 National Vice President-(IAPM)- 2013 Founder Chairperson -WB Chapter IAC (2017-2021)Chairperson-West Bengal Chapter of IAPM,2014. Ernest Fernandes Award from Indian Academy of Cytologists (IAC) in 1997 at AIIMS Dr.J.Nagalotimath Excellence in Teaching and Medical Academics Award from KLE University in 2011. Delivered “ Living Legend Symposium” in College of Dental Sciences, Davangere, Karnataka.in 2011 Key Note Address in 14th Indian Association of Oral and Maxillofacial Pathology in 2014. Life Time Achievement Award from Rajasthan Chapter of IAPM in 2009 at Kota and Jharkhand Chapter of IAPM in 2013 at Ranchi. Moderator in fourteen International , National IAPM and IAC Conferences. Organising Secretary and Scientific Chairpersons of National IAC Conferences 1996 and 2010

Speaker
Dr.Asitava Mondal / MD(PGI,Chandigarh) Clinical Cytologist and Oncopathologist, Kolkata Ex-Prof, NIH, Govt of India, Formerly, Thakurpukur Cancer Centre, Kolkata, Institute of Child Health, Kolkata, SVS Marwari Hospital and Cancer Centre, Kolkata President of ACH President of WBCS-2007-2011 President, Indian Academy of Cytologists (IAC)-2006 Vice-President, Indian Association of Pathologists and Microbiologists (IAPM)-2013

Abstract

A study in 1969 on bovine tuberculosis indicated a prevalence of 6.72% in animals in Faisalabad. In 1972, it was 2.9, 1.6 and 8.6% in buffalo, Australian cattle and Sahiwal cattle, respectively; in 1974 (Quetta) it was 0.53% in buffaloes. In 1989, it was 7.3% in cattle and buffaloes at Lahore abattoir. In 2001, it was 1.76% in buffaloes in Faisalabad. In 2003, in buffaloes and cattle prevalence was 6.91% and 8.64%, respectively in Lahore. In 2006, in buffaloes at two farms prevalence was 2.45 and 8.48%. In 2006-7, 2.2% prevalence in buffaloes at 11 farms was reported. A prevalence of 2.4% in goats and 0.9% in sheep at three and seven farms, respectively was reported, while in buffaloes, 3% prevalence around two cities of Punjab Pakistan was reported. In cattle a prevalence of 7.6% at 100% of public farms was reported. A prevalence of 3.3% in zoo animals has also been reported. The prevalence in sheep and goats was higher at farms, especially when small ruminants were kept with large ruminants and were low when lower number of total animals were present at same premises. It was speculated that some of the goat and sheep breeds are genetically resistant to tuberculosis. The stronger risk factors in cattle at 11 farms were the age of cattle, number of calving, total milk produced and lactation length. However, presence of sheep at cattle farm has protective effect on tuberculosis in cattle. Certain possible risk factors identified in buffaloes were lactating status of the buffalo, the presence of cattle at the farm, total number of cattle at the farm and the total number of animals at the farm. A higher OR of 2.1 for Nili Ravi breed suggests it being more susceptible to tuberculosis than Kundi breed of buffalo.

Biography

Dr. Tariq did Doctor of Veterinary Medicine in 1986, Master of Science (Pathology) in 1988 and PhD in 1998. He stood first in M.Sc (Hons) Pathology. He did postdoctorate in 2005 from Spain in Veterinary Public Health by having selected on merit by HEC in the very first batch. Dr. Tariq Joined University of Agriculture Faisalabad in February 1990 as lecturer and is serving as Professor since 2007. Completed three funded research projects, wrote seven books, and three chapters in International Books. Produced three PhDs and 51 M.Phil students, currently supervising three PhD students and 11 M.Phil students. Published 122 research paper in peer reviewed journals. He has worked for Pakistan Veterinary Journal from 1991 to 2010 as member of Editorial/Executive boards and acted as reviewer of more than 15 International Journals along with National Reviewer to evaluate research projects submitted for funding to two leading National Funding Agencies. Dr. Tariq represented Pakistan in a number of international conferences and meetings held in India (2006), Sri Lanka (2007), Malaysia (2010), China (2016) and Jordan (2018) as invited speaker. He has more than 12 presentations at national level as invited speaker. Dr. Tariq developed international collaboration with various international institutes including VISAVET, Madrid Spain, Instituto Zoo Profilatico, Perugia, Italy, Veterinary Research Institute, Sri Lanka and Bangladesh Agriculture, University. He got an MoU signed with the Italian institute to have collaborative research, sharing of literature, exchange of students etc. Dr. Tariq has arranged a number of national and international events and also has arranged a number of trainings.

Speaker
Prof. Dr. M. Tariq Javed / PhD, MSc, DVM, Postdoc (Spain) Chairman, Department of Pathology, Faculty of Veterinary Science, University of Agriculture, Faisalabad-38040, Pakistan.

Sessions Will be updated soon...

Will be updated soon...